There was a significant association between HbA1c and central corneal nerve fiber density, which further suggests that reduced corneal nerve fiber density begins to occur in the early stages of development toward type 2 diabetes. Although it was noted that subjects with type 2 diabetes were 15 years older than the healthy controls, studies examining the effect of aging on corneal nerve fiber density are contradictory. Based on the analysis, age was not a covariant affecting the corneal nerve fiber findings between groups. Some studies show that decreased nerve fiber density examined using in vivo confocal microscopy was associated with aging,
45,46 whereas other studies found that corneal nerve fiber density (mm/mm
2) was independent to aging in a healthy population.
47–51 However, Niederer et al. did not exclude subjects who may have systemic health issues.
45 Tavakoli et al. showed that nerve fiber density significantly decreased with aging in women (−0.06 mm/mm
2 per year) but not men (−0.045 mm/mm
2 per year) in a population age ranged between 8 and 82 years.
46 In addition, Dehgani et al. found a linear decrease in corneal nerve fiber density with age (−0.05 mm/mm
2 per year) in a senior population (52 ± 15 years old).
52 Based on the Tavakoli et al. and Dehgani et al. findings,
46,52 the differences in corneal nerve fiber density in this study between healthy and prediabetes (age difference: 11 years) or type 2 diabetes (15 years) were 0.50 to 0.66 mm/mm
2 and 0.68 to 0.90 mm/mm
2, which is less than the standard error of the differences of our results (1.55–1.62 mm/mm
2) and is unlikely contributing the differences between groups. In the current study, based on the inclusion of age as a covariant, age did not affect the association between corneal nerve fiber association and HbA1c concentration. This indicates that reduced corneal nerve fiber density may be an indicator of increased HbA1c concentration, independent of aging, and may serve as an early anterior segment alteration biomarker, which may appear prior to neuropathic changes in other areas of the body and end stage complications in type 2 diabetes, such as macular edema and diabetic retinopathy. However, it requires confirmation in future studies.